Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

45.03 -3.83 (-7.83%)
Streaming Delayed Price Updated: 11:50 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,013,940
Open 47.39
Bid (Size) 45.03 (3)
Ask (Size) 45.04 (2)
Prev. Close 48.86
Today's Range 44.67 - 47.50
52wk Range 47.58 - 70.94
Shares Outstanding 2,222,113,553
Dividend Yield 5.06%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024
BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Bristol-Myers Squibb layoffs will see the company reduce its headcount by 6% as part of an effort to reduce expenses in 2024. 
Via InvestorPlace
Topics Workforce
Exposures Layoff

Performance

YTD
-14.64%
-14.64%
1 Month
-13.81%
-13.81%
3 Month
-10.36%
-10.36%
6 Month
-20.45%
-20.45%
1 Year
-35.88%
-35.88%

More News

Read More
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Is Bristol Myers Squibb Stock a Millionaire Maker?
Via The Motley Fool
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
Via Investor's Business Daily
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Via Benzinga
5 Crash-Proof Stocks to Buy Immediately
Via InvestorPlace
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
From Bristol Myers Squibb
Via Business Wire
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
Via The Motley Fool
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Via InvestorPlace
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
Via InvestorPlace
Topics Stocks
Exposures US Equities
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Via The Motley Fool
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.